Skip navigation
Skip navigation

Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review

Madden, Rebecca; Kosari, Sam; Peterson, Gregory M; Bagheri, Nasser; Thomas, Jackson

Description

OBJECTIVE: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 - 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review...[Show more]

CollectionsANU Research Publications
Date published: 2018
Type: Journal article
URI: http://hdl.handle.net/1885/164690
Source: International Journal of Clinical Pharmacology and Therapeutics
DOI: 10.5414/CP203123

Download

File Description SizeFormat Image
01_Madden_Lapatinib_plus_capecitabine_in_2018.pdf443.96 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator